SONN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 apr 2024 @ 22:00):

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action...

Stats
Dagens volum	6 161.00
Gjennomsnittsvolum	104 046
Markedsverdi	5.66M
EPS	$0 ( 2024-02-14 )
Neste inntjeningsdato	( $0.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.22
ATR14	$0.0170 (0.92%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Rao Raghu	Buy	31 250	Warrant to Purchase Common Stock
2023-10-27	Rao Raghu	Buy	15 625	Common Stock
2023-10-27	Mohan Pankaj	Buy	68 750	Warrant to Purchase Common Stock
2023-10-27	Mohan Pankaj	Buy	34 375	Common Stock
2023-08-07	Markey John	Sell	0	Common Stock

INSIDER POWER
82.31
Last 88 transactions
Buy: 5 035 351 \| Sell: 2 861 714

Sonnet Biotherapeutics Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sonnet Biotherapeutics Økonomi

Annual	2023
Omsetning:	$147 805
Bruttogevinst:	$72 055.00 (48.75 %)
EPS:	$-18.14

Q1	2024
Omsetning:	$18 626.00
Bruttogevinst:	$-1 348.00 (-7.24 %)
EPS:	$-0.310

Q4	2023
Omsetning:	$37 255.00
Bruttogevinst:	$17 789.00 (47.75 %)
EPS:	$-2.10

Q3	2023
Omsetning:	$36 850.00
Bruttogevinst:	$17 873.00 (48.50 %)
EPS:	$-2.96

Financial Reports:

No articles found.

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.